MP-06.15: Discontinuous Alpha Blocker Therapy is a Feasible Strategy in Patients with LUTS that Leads to Cost Saving: An Important Issue in Developing Countries

Abstract

Alpha blockers are established therapy in patients (pts) with LUTS secondary to Benign Porstatic Obstruction (BPO) but are NOT curative. The exact duration of treatment and the need for continuous therapy, as mono-therapy, has not been thoroughly studied. This point is important as far as compliance, in men already on multiple medications, and COST especially in less wealthy developing countries. This study addresses the need for continuous alpha blocker therapy in pts with LUTS once response is established.